# A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors

> **NCT04857138** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 80 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** RO7300490
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04857138
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-18
- **Primary completion:** 2024-01-18
- **Final completion:** 2024-01-18
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04857138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04857138, "A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04857138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*